Loading
A phase 1/2 trial of REGN7075, Cemiplimab, Bevacizumab and Trifluridine/tipiracil in advanced solid tumours, run by Regeneron Pharmaceuticals, active and no longer recruiting.
A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers is a phase 1/2 interventional study registered as NCT04626635 by Regeneron Pharmaceuticals, with 548 participants enrolled, started 2020-12-21 and due to reach its primary completion in 2026-11-13. Interventions recorded: REGN7075, Cemiplimab, Platinum-based doublet chemotherapy, Bevacizumab and Trifluridine-tipiracil.
Shares Cemiplimab, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Trifluridine/tipiracil, Bevacizumab, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Bevacizumab, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Bevacizumab, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Bevacizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Bevacizumab, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Bevacizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.